Clinical Study of Allergic Rhinitis Therapy by Stem Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-13

Study Completion Date

2024-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators is now carrying out a clinical study of Umbilical cord Mesenchymal Stem Cells (UCMSCs) in the treatment of Allergic rhinitis (AR). UCMSCs is known to its multilineage differentiation potential, strong proliferation ability, low immunogenicity, convenient material acquisition, and fewer restrictions on ethical and moral issues. The investigators hope to find a novel, minimally invasive, effective and simple treatment for the large number of patients with persistent moderate to severe AR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microbial Study of Sublingual Immunotherapy Spray in Patients With Allergic Rhinitis

NCT06741787

Rhinitis, Allergic

NOT_YET_RECRUITING

Washed Microbiota Transplantation for Allergic Rhinitis

NCT06372184

Rhinitis, Allergic

NOT_YET_RECRUITING NA

Acupuncture for Nasal Congestion in Allergic Rhinitis

NCT05709977

Allergic Rhinitis

COMPLETED NA

Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients with Allergic Rhinitis

NCT05922176

Rhinitis, Allergic

RECRUITING

Washed Microbiota Transplantation for Rhinitis

NCT06350448

Rhinitis

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Allergic rhinitis (AR), is a noninfectious inflammatory disease of nasal mucosa mediated by immunoglobulin E (IgE) antibody and involved in a variety of immune active cells and cytokines after the atopic body is exposed to allergens. The incidence of allergic rhinitis increases as people's living standards improves. It is estimated that about 1.4 billion people worldwide have been affected by the disease. Some patients with moderate to severe AR have no improvement in symptoms after drug treatment, which continues to affect daily life and work. Therefore, these patients urgently needs a new, minimally invasive, effective and simple treatment. Mesenchymal Stem Cells (MSCs) are pluripotent stem cells derived from the mesoderm, which can differentiate into bone, cartilage, fat and other cells. MSCs can also secrete a variety of bioactive molecules, which have the effects of regulating immunity and anti-inflammatory. Based on its immunomodulatory effect, MSCs is gradually becoming a new star in the treatment of allergic diseases. In pre-clinical studies on the treatment of AR, MSCs have shown good therapeutic effect in the treatment of allergic rhinitis.

This study is a prospective, open, single-center clinical study. Participants were recruited into three different dose groups. The cohort size of each dose group was 6 participants. The subjects of each group each will receive one course of treatment with a single injection. Subjects of group 1 will receive 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs; group 2 will receive 1.0×10\^6 cells/kg; with a total volume of 100 ml UCMSCs; group 3 will receive 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs. One month after each injection, the Data and Safety Monitoring Committee (DSMC) will comprehensively evaluate the results of the phased clinical research, and after determining the safety and feasibility of the research, the enrollment of the next phase will start. The subjects will be followed up on the 3rd day, 1 week, 1 month, 3 months, 6 months, 12 months, and 24 months after the treatment. The main outcome measures are the severity and incidence of adverse events. The secondary outcome measures are RQLQ score, VAS score, serum inflammatory factor detection, nasal secretion inflammatory factor detection, nasal function test and nasal endoscopy, etc. In addition, the investigators will also monitor safety indicators such as blood routine, urine routine, liver and kidney function, immunological indicators, tumor markers, etc. At the end of the study, according to the data obtained, the clinical safety and feasibility of intravenous infusion of UCMSCs in the treatment of moderate to severe persistent AR will be evaluated, so as to provide drug dose basis for the next stage of clinical research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose UCMSCs

Group Type EXPERIMENTAL

Low dose UCMSCs

Intervention Type BIOLOGICAL

Receive one course of treatment with a single injection : 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

Moderate dose UCMSCs

Group Type EXPERIMENTAL

Moderate dose UCMSCs

Intervention Type BIOLOGICAL

Receive one course of treatment with a single injection : 1.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

High dose UCMSCs

Group Type EXPERIMENTAL

High dose UCMSCs

Intervention Type BIOLOGICAL

Receive one course of treatment with a single injection : 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low dose UCMSCs

Receive one course of treatment with a single injection : 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

Intervention Type BIOLOGICAL

Moderate dose UCMSCs

Receive one course of treatment with a single injection : 1.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

Intervention Type BIOLOGICAL

High dose UCMSCs

Receive one course of treatment with a single injection : 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with moderate to severe persistent allergic rhinitis who meet the diagnostic criteria for allergic rhinitis (2015 Tianjin standard);
2. The results of allergen examination showed that the allergen was a single allergy of dust mite;
3. After more than 2 years of antihistamine, nasal glucocorticoid and other drug treatments, the curative effect is poor, and the symptoms seriously affect the patient's life;
4. Age 18-60 years old;
5. The patient refused to receive allergen-specific immunotherapy;
6. The patient is willing to receive stem cell therapy and sign an informed consent.

Exclusion Criteria

1. The subject is accompanied by sinusitis, asthma and aspirin intolerance;
2. The subjects suffer from severe primary heart, liver, lung, kidney and blood diseases;
3. The subjects suffer from Malignant tumors;
4. The subjects suffer from severe immune diseases;
5. The subjects suffer from mental illness;
6. Female subjects who are or are about to become pregnant, pregnant or breastfeeding;
7. Patients who are participating in other clinical trials;
8. In addition to the above conditions, there are other reasons why researchers believe that they are not suitable to participate in this clinical study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No